Table 6.

Clinical characteristics of the SARS-CoV-2 infected and uninfected patients (n = 200).

Characteristic	SARS-CoV-2 infected participants (n = 179)	SARS-CoV-2 uninfected participants (n = 21)	X2	p-value
Sex
Male	95 (53.1%)	12 (57.1%)	0.125	0.724
Female	84 (46.9%)	9 (42.9%)
Age group, years
< 60	120 (67.0%)	8 (38.1%)	6.834	0.009
≥ 60	59 (33.0%)	13 (61.9%)
Type of diabetes
Type 1	15 (8.4%)	1 (4.8%)	0.757	0.86 a
Type 2	147 (82.1%)	18 (85.7%)
Unclassified diabetes	14 (7.8%)	2 (9.5%)
Others	3 (1.7%)	0
Chronic disease
Hypertension	68 (38.0%)	8 (38.1%)	0.00009	0.992
Hyperlipidemia	91 (50.8%)	12 (57.1%)	0.299	0.584
Metabolic syndrome	5 (2.8%)	0	0.602	1 a
Chronic respiratory disease	9 (5.0%)	0	1.106	0.602 a
Cardiovascular and cerebrovascular diseases	33 (18.4%)	0	4.637	0.028 a
Liver or kidney diseases	15 (8.4%)	1 (4.8%)	0.334	1 a
Inflammatory immune diseases	3 (1.7%)	1 (4.8%)	0.913	0.361 a
Cancer	8 (4.5%)	0	0.978	1 a
Others	6 (3.4%)	2 (9.5%)	1.864	0.2 a
No	49 (27.4%)	6 (28.6%)	0.014	0.907
Diabetes complications
Diabetic eye disease	26 (14.5%)	1 (4.8%)	1.534	0.32 a
Diabetic Nephropathy	13 (7.3%)	1 (4.8%)	0.181	1 a
Diabetic foot	2 (1.1%)	0	0.237	1 a
Diabetic neuropathy	11 (6.1%)	0	1.366	0.61 a
No	137 (76.5%)	19 (90.5%)	2.128	0.174
Time since diabetes diagnosis, years
≤1	20 (11.2%)	0	3.523	0.172 a
1–10	74 (41.3%)	12 (57.1%)
≧10	85 (47.5%)	9 (42.9%)
COVID-19 vaccination status
Unvaccinated	39 (21.8%)	4 (19.0%)	6.32	0.176 a
One vaccine dose	2 (1.1%)	1 (4.8%)
Two vaccine doses	23 (12.8%)	0
Three vaccine doses	109 (60.9%)	14 (66.7%)
Four vaccine doses	6 (3.4%)	2 (9.6%)
Cohabitant infected with SARS-COV-2
Yes	163 (91.1%)	12 (57.1%)	19.77	< 0.001
No	16 (8.9%)	9 (42.9%)

^ap-value for Fisher’s exact test, others for the Chi-square test.

Bold values show significant differences (P< 0.05).